Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
AbstractImmunotherapy has emerged as one of the most promising approaches for ovarian cancer treatment. The tumor microenvironment (TME) is a key factor to consider when stimulating antitumoral responses as it consists largely of tumor promoting immunosuppressive cell types that attenuate antitumor immunity. As our understanding of the determinants of the TME composition grows, we have begun to appreciate the need to address both inter- and intra-tumor heterogeneity, mutation/neoantigen burden, immune landscape, and stromal cell contributions. The majority of immunotherapy studies in ovarian cancer have been performed using the well-characterized murine ID8 ovarian carcinoma model. Numerous other animal models of ovarian cancer exist, but have been underutilized because of their narrow initial characterizations in this context. Here, we describe animal models that may be untapped resources for the immunotherapy field because of their shared genomic alterations and histopathology with human ovarian cancer. We also shed light on the strengths and limitations of these models, and the knowledge gaps that need to be addressed to enhance the utility of preclinical models for testing novel immunotherapeutic approaches. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
McCloskey, C.W.; Rodriguez, G.M.; Galpin, K.J.C.; Vanderhyden, B.C. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers 2018, 10, 244.
McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers. 2018; 10(8):244.Chicago/Turabian Style
McCloskey, Curtis W.; Rodriguez, Galaxia M.; Galpin, Kristianne J.C.; Vanderhyden, Barbara C. 2018. "Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics." Cancers 10, no. 8: 244.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.